Medpace Holdings company profile
Company profile
Medpace Holdings has 6,600 employees and is headquartered in Cincinnati, United States.
Clinical trial work for drug and medical device developers is delivered across Australia, Africa, South America, Asia, Europe and North America. The company runs studies from Phase I through Phase IV for pharmaceutical, biotechnology and medical device sponsors active in a broad set of therapeutic areas. Its range covers study design, central laboratory coordination, regulatory submissions, post-marketing support, bio-analytical laboratory services, clinical pharmacology, imaging and electrocardiography reading for trials.
The company was founded in 1992 and is headquartered in Cincinnati, Ohio, with 6,600 employees. In the fiscal year ended December 2025, revenue reached 2,530.2 million US dollars, up 20.0% from the previous year, and net income was 451.1 million US dollars.
Company facts
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Country
- United States
- Headquarters
- 5375 Medpace Way, 45227, Cincinnati
- Employees
- 6,600
- Chief executive
- August Troendle
- Founded
- 1992
- Fiscal year
- January - December
- Listing
- MEDP · NASDAQ
- Currency
- USD
- ISIN
- US58506Q1094
- Website
- medpace.com
Medpace Holdings and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| Medpace HoldingsMEDP | United States | $18.27B | 6,600 | 21.4% | 36.3 |
| RevvityRVTY | United States | $17.84B | 11,000 | 16.3% | 70.5 |
| Guardant HealthGH | United States | $20.52B | 2,490 | -39.4% | — |
| Charles River Laboratories InternationalCRL | United States | $16.19B | 18,300 | 14.3% | 367.4 |
| ICON PublicICLR | United States | $14.58B | 40,250 | 2.7% | 77.9 |
| Quest DiagnosticsDGX | United States | $28.85B | 60,000 | 14.9% | 26.1 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
